Loading…
Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism
Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contributi...
Saved in:
Published in: | Biomedicine & pharmacotherapy 2023-11, Vol.167, p.115430-115430, Article 115430 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703 |
---|---|
cites | cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703 |
container_end_page | 115430 |
container_issue | |
container_start_page | 115430 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 167 |
creator | Sun, Xiongjie Zhang, Yu Cheng, Gang Zhu, Tianxiang Zhang, Zhigang Xiong, Lei Hu, Haiming Liu, Hongtao |
description | Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC.
[Display omitted]
•Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling. |
doi_str_mv | 10.1016/j.biopha.2023.115430 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2863305480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332223012283</els_id><sourcerecordid>2863305480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</originalsourceid><addsrcrecordid>eNp9kLtOAzEQRS0EEiHwBxQuaTaM1-t9NEgQnlIkikBtee1ZMtE-gr1Byt_jaKmZZoqZe6R7GLsWsBAg8tvtoqZhtzGLFFK5EEJlEk7YTFQKkhygOGUzKJRMpEzTc3YRwhYAVC7LGWsf0NfoqUdO3c4PPxj443qdUO_2Fh23Q0sjBU4978girw-8G9y-NSP1X3zcIG_QmjapjR0jxiQe4y0Ga2qRG0uOdziaOmJCd8nOGtMGvPrbc_b5_PSxfE1W7y9vy_tVYmWpxkRUJeapRBtHxkaZNUpVqrJCGVW5HCpbuKq2pZGmyUUJZVogoESXuaopQM7ZzcSNhb73GEbdUbDYtqbHYR90WuZSgsrK42s2vVo_hOCx0TtPnfEHLUAf5eqtnuTqo1w9yY2xuymGscYPodfBEvbRGHm0o3YD_Q_4BXQ-hVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2863305480</pqid></control><display><type>article</type><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><source>ScienceDirect Journals</source><creator>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</creator><creatorcontrib>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</creatorcontrib><description>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC.
[Display omitted]
•Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2023.115430</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Berberine ; Gut microbiota ; Intestinal metabolites, Bile acids ; Ulcerative colitis</subject><ispartof>Biomedicine & pharmacotherapy, 2023-11, Vol.167, p.115430-115430, Article 115430</ispartof><rights>2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</citedby><cites>FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</cites><orcidid>0000-0003-0149-6389</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Sun, Xiongjie</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Cheng, Gang</creatorcontrib><creatorcontrib>Zhu, Tianxiang</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Xiong, Lei</creatorcontrib><creatorcontrib>Hu, Haiming</creatorcontrib><creatorcontrib>Liu, Hongtao</creatorcontrib><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><title>Biomedicine & pharmacotherapy</title><description>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC.
[Display omitted]
•Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</description><subject>Berberine</subject><subject>Gut microbiota</subject><subject>Intestinal metabolites, Bile acids</subject><subject>Ulcerative colitis</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOAzEQRS0EEiHwBxQuaTaM1-t9NEgQnlIkikBtee1ZMtE-gr1Byt_jaKmZZoqZe6R7GLsWsBAg8tvtoqZhtzGLFFK5EEJlEk7YTFQKkhygOGUzKJRMpEzTc3YRwhYAVC7LGWsf0NfoqUdO3c4PPxj443qdUO_2Fh23Q0sjBU4978girw-8G9y-NSP1X3zcIG_QmjapjR0jxiQe4y0Ga2qRG0uOdziaOmJCd8nOGtMGvPrbc_b5_PSxfE1W7y9vy_tVYmWpxkRUJeapRBtHxkaZNUpVqrJCGVW5HCpbuKq2pZGmyUUJZVogoESXuaopQM7ZzcSNhb73GEbdUbDYtqbHYR90WuZSgsrK42s2vVo_hOCx0TtPnfEHLUAf5eqtnuTqo1w9yY2xuymGscYPodfBEvbRGHm0o3YD_Q_4BXQ-hVg</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Sun, Xiongjie</creator><creator>Zhang, Yu</creator><creator>Cheng, Gang</creator><creator>Zhu, Tianxiang</creator><creator>Zhang, Zhigang</creator><creator>Xiong, Lei</creator><creator>Hu, Haiming</creator><creator>Liu, Hongtao</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0149-6389</orcidid></search><sort><creationdate>202311</creationdate><title>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</title><author>Sun, Xiongjie ; Zhang, Yu ; Cheng, Gang ; Zhu, Tianxiang ; Zhang, Zhigang ; Xiong, Lei ; Hu, Haiming ; Liu, Hongtao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Berberine</topic><topic>Gut microbiota</topic><topic>Intestinal metabolites, Bile acids</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Xiongjie</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Cheng, Gang</creatorcontrib><creatorcontrib>Zhu, Tianxiang</creatorcontrib><creatorcontrib>Zhang, Zhigang</creatorcontrib><creatorcontrib>Xiong, Lei</creatorcontrib><creatorcontrib>Hu, Haiming</creatorcontrib><creatorcontrib>Liu, Hongtao</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Xiongjie</au><au>Zhang, Yu</au><au>Cheng, Gang</au><au>Zhu, Tianxiang</au><au>Zhang, Zhigang</au><au>Xiong, Lei</au><au>Hu, Haiming</au><au>Liu, Hongtao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><date>2023-11</date><risdate>2023</risdate><volume>167</volume><spage>115430</spage><epage>115430</epage><pages>115430-115430</pages><artnum>115430</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Ulcerative colitis (UC) has been confirmed as a disease with a high incidence and low cure rate worldwide. In severe cases, UC can develop into colon cancer. Modern research has confirmed that berberine (BBR) can treat UC by inhibiting the expressions of inflammatory factors. However, the contribution of gut microbiota and flora metabolites in treating UC with BBR remains unclear. In this study, the ameliorative effects of BBR on gut microbiota dysbiosis and flora metabolites were investigated in a dextran sodium sulfate (DSS)-induced UC rodent model. We found that BBR significantly improved the pathological phenotype, attenuated intestinal barrier disruption, and mitigated colonic inflammation in DSS mice. By 16 S rDNA sequencing, BBR alleviated gut microbiota dysbiosis in UC mice. Moreover, the gut microbiota depletion experiment confirmed that the therapeutic effect of BBR was inextricably correlated with the gut microbiota. Besides, the flora metabolites (e.g., short-chain fatty acids, bile acids, and 5-hydroxytryptamine) were studied using HPLC-MS. The results suggested that BBR ameliorated the bile acid imbalance induced by DSS in the liver and gut. Furthermore, BBR treatment repaired gut barrier damage. The above results revealed that BBR alleviated DSS-induced UC in mice by restoring the disturbed gut microbiota, elevating unconjugated and secondary bile acids in the gastrointestinal tract, and activating the FXR and TGR5 signal pathway. This study provides novel insights into the mechanism of BBR in treating UC.
[Display omitted]
•Berberine suppressed colonic inflammation and increased gut barrier integrity.•Berberine reversed the imbalance of gut microbiota and bacterial metabolites.•Berberine regulated bile acid levels by increasing Lactobacillus and Roseburia.•Berberine modulated bile acid metabolism through activating FXR-TGR5 signaling.</abstract><pub>Elsevier Masson SAS</pub><doi>10.1016/j.biopha.2023.115430</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0149-6389</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2023-11, Vol.167, p.115430-115430, Article 115430 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2863305480 |
source | ScienceDirect Journals |
subjects | Berberine Gut microbiota Intestinal metabolites, Bile acids Ulcerative colitis |
title | Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T07%3A26%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Berberine%20improves%20DSS-induced%20colitis%20in%20mice%20by%20modulating%20the%20fecal-bacteria-related%20bile%20acid%20metabolism&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Sun,%20Xiongjie&rft.date=2023-11&rft.volume=167&rft.spage=115430&rft.epage=115430&rft.pages=115430-115430&rft.artnum=115430&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2023.115430&rft_dat=%3Cproquest_cross%3E2863305480%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c385t-198e623ecccc30234ca55959c15a59d609c7d9bc8a3af6180827e0e3ed4d9f703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2863305480&rft_id=info:pmid/&rfr_iscdi=true |